Jiangsu Nhwa Pharmaceutical vs Zhejiang Huahai Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Jiangsu Nhwa Pharmaceutical Co Ltd (002262.CS)

Q3 202617 Aug – 29 Sep 2026

▲2

Nhwa's H1 profit rises 5.7% on fast-growing neurology drugs; pipeline and AI bets advance

First-half profit and revenue grew, led by neurology products Nhwa's first-half net profit rose 5.7% to 741 million yuan and revenue rose 6.9% to 3.218 billion yuan. Neurology product sales jumped 33.7%, the fastest-growing core segment, while anesthetics and psychiatric drugs also grew. Steady profit growth supports the share price.
The half-year results are the period's main hard financial news and show the core business still growing.
Cash flow and margins weakened even as profit rose Operating cash flow fell 43.3% to 280 million yuan, and gross margin slipped 1.38 points to 73.86%. Profit still grew, but weaker cash generation and margins are a real counterweight that can cap gains or make investors cautious.
It is the main negative in the results and gives a fair, balanced picture of the period.
New drug pipeline advances, including a new clinical approval Nhwa's Class 1 drug NH302 injection won clinical trial approval for treating acute pain. Its innovative drug NH600001 has been submitted for marketing approval, and schizophrenia drug NHL35700 entered Phase III. A richer pipeline raises hopes for future growth.
Pipeline progress is a key long-term value driver and includes a genuinely new approval this period.
AI mental-health unit raises 262 million yuan, diluting Nhwa slightly Investee Haoxinqing will raise 262 million yuan from seven new investors to fund AI psychological companion robots and digital mental-health tools. Nhwa waived its right to subscribe, so its stake falls from 19.10% to 18.04%, but it stays the largest shareholder.
It is the period's main corporate action and shows both an AI growth bet and mild dilution.

September 202617 Aug – 29 Sep 2026

▲2

Nhwa's H1 profit rises 5.7% on fast-growing neurology drugs; pipeline and AI bets advance

First-half profit and revenue grew, led by neurology products Nhwa's first-half net profit rose 5.7% to 741 million yuan and revenue rose 6.9% to 3.218 billion yuan. Neurology product sales jumped 33.7%, the fastest-growing core segment, while anesthetics and psychiatric drugs also grew. Steady profit growth supports the share price.
The half-year results are the period's main hard financial news and show the core business still growing.
Cash flow and margins weakened even as profit rose Operating cash flow fell 43.3% to 280 million yuan, and gross margin slipped 1.38 points to 73.86%. Profit still grew, but weaker cash generation and margins are a real counterweight that can cap gains or make investors cautious.
It is the main negative in the results and gives a fair, balanced picture of the period.
New drug pipeline advances, including a new clinical approval Nhwa's Class 1 drug NH302 injection won clinical trial approval for treating acute pain. Its innovative drug NH600001 has been submitted for marketing approval, and schizophrenia drug NHL35700 entered Phase III. A richer pipeline raises hopes for future growth.
Pipeline progress is a key long-term value driver and includes a genuinely new approval this period.
AI mental-health unit raises 262 million yuan, diluting Nhwa slightly Investee Haoxinqing will raise 262 million yuan from seven new investors to fund AI psychological companion robots and digital mental-health tools. Nhwa waived its right to subscribe, so its stake falls from 19.10% to 18.04%, but it stays the largest shareholder.
It is the period's main corporate action and shows both an AI growth bet and mild dilution.

Latest17 Aug – 29 Sep 2026

▲2

Nhwa's H1 profit rises 5.7% on fast-growing neurology drugs; pipeline and AI bets advance

First-half profit and revenue grew, led by neurology products Nhwa's first-half net profit rose 5.7% to 741 million yuan and revenue rose 6.9% to 3.218 billion yuan. Neurology product sales jumped 33.7%, the fastest-growing core segment, while anesthetics and psychiatric drugs also grew. Steady profit growth supports the share price.
The half-year results are the period's main hard financial news and show the core business still growing.
Cash flow and margins weakened even as profit rose Operating cash flow fell 43.3% to 280 million yuan, and gross margin slipped 1.38 points to 73.86%. Profit still grew, but weaker cash generation and margins are a real counterweight that can cap gains or make investors cautious.
It is the main negative in the results and gives a fair, balanced picture of the period.
New drug pipeline advances, including a new clinical approval Nhwa's Class 1 drug NH302 injection won clinical trial approval for treating acute pain. Its innovative drug NH600001 has been submitted for marketing approval, and schizophrenia drug NHL35700 entered Phase III. A richer pipeline raises hopes for future growth.
Pipeline progress is a key long-term value driver and includes a genuinely new approval this period.
AI mental-health unit raises 262 million yuan, diluting Nhwa slightly Investee Haoxinqing will raise 262 million yuan from seven new investors to fund AI psychological companion robots and digital mental-health tools. Nhwa waived its right to subscribe, so its stake falls from 19.10% to 18.04%, but it stays the largest shareholder.
It is the period's main corporate action and shows both an AI growth bet and mild dilution.

Zhejiang Huahai Pharmaceutical Co Ltd (600521.CG)

Q3 202624 Jul – 7 Oct 2026

▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.
This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.
Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.
A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.
Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.
Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.
US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.
These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.

August 202624 Jul – 7 Oct 2026

▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.
This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.
Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.
A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.
Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.
Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.
US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.
These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.

Latest24 Jul – 7 Oct 2026

▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.
This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.
Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.
A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.
Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.
Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.
US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.
These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.